Sunshine Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sunshine Biopharma (SBFM).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$70Upside to Avg. PT+9900.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2025	Aegis Capital	David Bouchey	Maintained	Buy	$7
Dec 5, 2024	Aegis Capital	David Bouchey	Maintained	Buy	$15

Analyst Ratings News

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:SBFM) with a Buy and maintains $7 price target.

Benzinga Newsdesk

US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia

U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in premarket trading.

Rishabh Mishra

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:SBFM) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
Aegis Capital Initiates Coverage On Sunshine Biopharma with Buy Rating, Announces Price Target of $2.6

Aegis Capital analyst David Bouchey initiates coverage on Sunshine Biopharma (NASDAQ:SBFM) with a Buy rating and announces Price Target of $2.6.

Benzinga Newsdesk

Sunshine Biopharma Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Sunshine Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

PRO
Aegis Capital Initiates Coverage On Sunshine Biopharma with Buy Rating, Announces Price Target of $2.6

People Also Watch

People Also Watch

Sunshine Biopharma Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Sunshine Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia

PROAegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

PROAegis Capital Initiates Coverage On Sunshine Biopharma with Buy Rating, Announces Price Target of $2.6

People Also Watch

People Also Watch

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

PRO
Aegis Capital Initiates Coverage On Sunshine Biopharma with Buy Rating, Announces Price Target of $2.6